Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 9 de 9
1.
Dermatol Surg ; 50(1): 1-4, 2024 Jan 01.
Article En | MEDLINE | ID: mdl-37792670

BACKGROUND: Novel oral anticoagulants (NOACs) are commonly prescribed, recently developed anticoagulants, but limited data exist on NOAC-related bleeding complications in Mohs micrographic surgery (MMS). OBJECTIVE: To assess the risk of postoperative bleeding in patients taking NOACs compared with patients taking no antithrombotic medications. METHODS/MATERIALS: A 5-year retrospective chart review of all MMS cases performed by a single surgeon was conducted. Patient and surgery characteristics, anticoagulant use, and bleeding complications were recorded. RESULTS: Two thousand one hundred eighty-one MMS cases in 1,545 patients were included. There were 696/2,181 cases in which patients were taking at least 1 antithrombotic medication, with 149 on NOAC monotherapy and 15 on NOAC and aspirin combination therapy. Bleeding complications occurred in 22/2,181 cases. Patients on NOAC monotherapy did not have an increased risk of bleeding complications compared with patients on no antithrombotic medications (odds ratio [OR]:1.70, 95% confidence interval [CI]: 0.36-7.97, p = .50). In contrast, patients on NOAC and aspirin combination therapy exhibited an increased bleeding risk (OR: 20.5, 95% CI: 3.99-105.7, p < .001). CONCLUSION: Novel oral anticoagulant use alone during MMS was not associated with an increased postoperative bleeding risk, supporting the safety of continuing NOAC therapy during MMS. However, NOAC and aspirin combination therapy was associated with a high postoperative bleeding risk. Nonetheless, these bleeding events did not lead to adverse long-term outcomes.


Anticoagulants , Atrial Fibrillation , Humans , Anticoagulants/adverse effects , Retrospective Studies , Administration, Oral , Mohs Surgery/adverse effects , Postoperative Hemorrhage/chemically induced , Postoperative Hemorrhage/epidemiology , Aspirin/adverse effects , Atrial Fibrillation/drug therapy
6.
Pediatr Dermatol ; 36(6): 1010-1011, 2019 Nov.
Article En | MEDLINE | ID: mdl-31414503

Syndromes associated with desmosomal protein mutations such as desmoplakin can result in hair abnormalities including congenital alopecia and hypotrichosis. Herein, we present an 8-year-old boy, with a combination of two heterozygous mutations in the DSP gene encoding desmoplakin associated with congenital alopecia and long-standing hypotrichosis, who was treated with off-label use of topical minoxidil 5% foam once daily with dramatic growth after 2 months of therapy and sustained results at 1 year. Topical minoxidil may be effective in management of congenital alopecia and hypotrichosis associated with desmoplakin mutations.


Alopecia/drug therapy , Desmoplakins/genetics , Genetic Diseases, X-Linked/drug therapy , Hypotrichosis/drug therapy , Minoxidil/therapeutic use , Mutation , Administration, Topical , Alopecia/genetics , Child , Dermatologic Agents/therapeutic use , Genetic Diseases, X-Linked/genetics , Humans , Hypotrichosis/genetics , Male , Off-Label Use
7.
JAMA Dermatol ; 153(3): 296-303, 2017 03 01.
Article En | MEDLINE | ID: mdl-28097368

Importance: Skin cancer is the most common malignancy occurring after organ transplantation. Although previous research has reported an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has estimated the posttransplant population-based incidence in the United States. Objective: To determine the incidence and evaluate the risk factors for posttransplant skin cancer, including squamous cell carcinoma (SCC), melanoma (MM), and Merkel cell carcinoma (MCC) in a cohort of US OTRs receiving a primary organ transplant in 2003 or 2008. Design, Setting, and Participants: This multicenter retrospective cohort study examined 10 649 adult recipients of a primary transplant performed at 26 centers across the United States in the Transplant Skin Cancer Network during 1 of 2 calendar years (either 2003 or 2008) identified through the Organ Procurement and Transplantation Network (OPTN) database. Recipients of all organs except intestine were included, and the follow-up periods were 5 and 10 years. Main Outcomes and Measures: Incident skin cancer was determined through detailed medical record review. Data on predictors were obtained from the OPTN database. The incidence rates for posttransplant skin cancer overall and for SCC, MM, and MCC were calculated per 100 000 person-years. Potential risk factors for posttransplant skin cancer were tested using multivariate Cox regression analysis to yield adjusted hazard ratios (HR). Results: Overall, 10 649 organ transplant recipients (mean [SD] age, 51 [12] years; 3873 women [36%] and 6776 men [64%]) contributed 59 923 years of follow-up. The incidence rates for posttransplant skin cancer was 1437 per 100 000 person-years. Specific subtype rates for SCC, MM, and MCC were 812, 75, and 2 per 100 000 person-years, respectively. Statistically significant risk factors for posttransplant skin cancer included pretransplant skin cancer (HR, 4.69; 95% CI, 3.26-6.73), male sex (HR, 1.56; 95% CI, 1.34-1.81), white race (HR, 9.04; 95% CI, 6.20-13.18), age at transplant 50 years or older (HR, 2.77; 95% CI, 2.20-3.48), and being transplanted in 2008 vs 2003 (HR, 1.53; 95% CI, 1.22-1.94). Conclusions and Relevance: Posttransplant skin cancer is common, with elevated risk imparted by increased age, white race, male sex, and thoracic organ transplantation. A temporal cohort effect was present. Understanding the risk factors and trends in posttransplant skin cancer is fundamental to targeted screening and prevention in this population.


Carcinoma, Merkel Cell/epidemiology , Carcinoma, Squamous Cell/epidemiology , Melanoma/epidemiology , Organ Transplantation/statistics & numerical data , Skin Neoplasms/epidemiology , Adolescent , Adult , Age Factors , Aged , Carcinoma, Merkel Cell/ethnology , Carcinoma, Squamous Cell/ethnology , Female , Follow-Up Studies , Humans , Incidence , Male , Melanoma/ethnology , Middle Aged , Retrospective Studies , Risk Factors , Sex Factors , Skin Neoplasms/ethnology , United States/epidemiology , White People/statistics & numerical data , Young Adult
9.
mBio ; 6(2)2015 Apr 21.
Article En | MEDLINE | ID: mdl-25900653

UNLABELLED: Skin is the most common site of Staphylococcus aureus infection. While most of these infections are self-limited, recurrent infections are common. Keratinocytes and recruited immune cells participate in skin defense against infection. We postulated that S. aureus is able to adapt to the milieu within human keratinocytes to avoid keratinocyte-mediated clearance. From a collection of S. aureus isolated from chronically infected patients with atopic dermatitis, we noted 22% had an agr mutant-like phenotype. Using several models of human skin infection, we demonstrate that toxin-deficient, agr mutants of methicillin-resistant S. aureus (MRSA) USA300 are able to persist within keratinocytes by stimulating autophagy and evading caspase-1 and inflammasome activation. MRSA infection induced keratinocyte autophagy, as evidenced by galectin-8 and LC3 accumulation. Autophagy promoted the degradation of inflammasome components and facilitated staphylococcal survival. The recovery of more than 58% agr or RNAIII mutants (P < 0.0001) of an inoculum of wild-type (WT) MRSA from within wortmannin-treated keratinocytes compared to control keratinocytes reflected the survival advantage for mutants no longer expressing agr-dependent toxins. Our results illustrate the dynamic interplay between S. aureus and keratinocytes that can result in the selection of mutants that have adapted specifically to evade keratinocyte-mediated clearance mechanisms. IMPORTANCE: Human skin is a major site of staphylococcal infection, and keratinocytes actively participate in eradication of these pathogens. We demonstrate that methicillin-resistant Staphylococcus aureus (MRSA) is ingested by keratinocytes and activates caspase-1-mediated clearance through pyroptosis. Toxin-deficient MRSA mutants are selected within keratinocytes that fail to induce caspase-1 activity and keratinocyte-mediated clearance. These intracellular staphylococci induce autophagy that enhances their intracellular survival by diminishing inflammasome components. These findings suggest that S. aureus mutants, by exploiting autophagy, can persist within human keratinocytes.


Keratinocytes/microbiology , Methicillin-Resistant Staphylococcus aureus/physiology , Adaptation, Biological , Animals , Autophagy , Bacterial Proteins , Bacterial Toxins/metabolism , Humans , Immune Evasion , Mice , Trans-Activators/deficiency
...